GSK

News

GSK bows to Trump pressure and pauses diversity policies

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

Vaccines production line at GSK facility in Wavre, Belgium

GSK gets ready for its next big vaccine launch

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

News

Stopwatch starts on reviews of GSK's long-acting asthma drug

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

News

GSK backs £50m Oxford University cancer vaccine programme

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

GSK bows to Trump pressure and pauses diversity policies

FDA sets June date for Gilead's twice-yearly HIV PrEP

GSK gets ready for its next big vaccine launch

GSK rides out vaccine sales weakness with cancer, HIV gains

Stopwatch starts on reviews of GSK's long-acting asthma drug

GSK backs £50m Oxford University cancer vaccine programme

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks